NurExone Appoints Eyal Gabbai To Board As It Prepares For Clinical Milestones

NurExone Biologic has announced a change to its board of directors, with Eyal Gabbai joining the board effective immediately following the resignation of Dr Gadi Riesenfeld. While stepping down from his board role, Dr. Riesenfeld will continue to support the company as a member of its Scientific Advisory Board. NurExone said the transition reflects its ongoing evolution as it advances preclinical regenerative medicine programs toward first-in-human studies and considers future capital markets activities.

The company highlighted that Gabbai’s background in healthcare leadership and global finance is expected to strengthen its strategic direction during this next stage of development. His experience working with international investors and navigating large healthcare systems is considered particularly valuable as NurExone prepares for key clinical and corporate milestones.

“This appointment reflects our focus on engaging with partners who understand both patient needs and the economics of healthcare,” said Yoram Drucker, Chairman of NurExone. “Eyal brings deep experience across healthcare systems, technology adoption, market implementation, as well as a strong understanding of public company and regulated environments. His perspective will be valuable as we continue to build NurExone’s platform and engage with global partners, public-market stakeholders, and investors.”

Gabbai currently serves as chairman of Meuhedet Health Fund, one of Israel’s largest health maintenance organisations, as well as chairman of Medica Excel’s private hospital network. Earlier in his career, he held senior government roles, including Director-General of Israel’s Prime Minister’s Office and Director General of the Government Companies Authority, where he oversaw large-scale privatisations and public market transactions totalling more than $5 billion.

“I chose to join NurExone because of the strength of its technology and science and the disciplined way the team is approaching development in an area of medicine where current solutions are not good enough,” said Eyal Gabbai. “Exosome-based therapies hold significant potential, and NurExone is advancing this field with a clear focus on data and execution. I also value the Company’s dual outlook, pursuing nearer-term opportunities through exosome supply and collaborations, while building longer-term potential through advancing proprietary drug candidates.”

NurExone also expressed its appreciation for Dr Riesenfeld’s contributions, noting that he played a key role during a period of platform expansion and increased global engagement for the company. His continued involvement through the Scientific Advisory Board is expected to help maintain scientific continuity.